Evidence map›Paper›PMID 31010420›Full record

ReviewAlzheimer's research & therapy2019

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer's Disease.

Oskar Hansson, Sylvain Lehmann, Markus Otto, Henrik Zetterberg, Piotr Lewczuk

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Alzheimer's research & therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 315 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
315citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

315 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Utility of cortical tissue analysis in normal pressure hydrocephalus.Cerebral cortex (New York, N.Y. : 1991) · 2024
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

255 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Oskar HanssonClinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malmö, Sweden.
Sylvain LehmannCenter of Excellence for Neurodegenerative disorders (COEN) of Montpellier, Montpellier University, CHU Montpellier, INSERM, Montpellier, France.
Markus OttoDepartment of Neurology, University of Ulm, Ulm, Germany.
Henrik ZetterbergClinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
Piotr LewczukDepartment of Psychiatry and Psychotherapy, Universitätsklinikum Erlangen and Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen, Germany. Piotr.Lewczuk@uk-erlangen.de.ORCID 0000-0002-8101-6535

Funding

Fujirebio Europe N/AInnovative Medicines Initiative Joint Undertaking EMIF 115372Swedish Research Council N/A
6 · The paper itself

Abstract

The cerebrospinal fluid (CSF) biochemical markers (biomarkers) Amyloidβ 42 (Aβ

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesBiomarkersHumansPeptide FragmentsAmyloid beta-Peptidesamyloid beta-protein (1-40)amyloid beta-protein (1-42)BiomarkersPeptide FragmentsAlzheimer’s DiseaseAmyloidβ PeptidesAβ42/40 ratioBiomarkersCerebrospinal Fluid

Identifiers

PMID31010420
PMCPMC6477717

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.